Use of Endogenous Melatonin and 6-hydroxymelatonin as Biomarkers for CYP1A2
NCT04420611 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12
Last updated 2023-05-11
Summary
An observational study comprising 4 sessions will be conducted in 12 healthy volunteers. During each study session (sessions 1 to 4), a 12-hour urine collection during the night (21h-9h) will be carried out by each participant. The first urine in the morning will be collected separately to be analysed independently of the 12-hour collection. 24 hours before the start of the night urine collection, volunteers will be asked to refrain from consuming alcohol and caffeinated drinks/foods, with the exception of session 3. Conversely, in session 3, subjects will be asked to drink or eat caffeinated food/drinks 24 hours prior to night-time urine collection (at least one cup of coffee or a can of Coca-Cola®).
After each 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®.
Conditions
- Healthy
Interventions
- OTHER
-
Session 1 (day 1)
12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods. After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®.
- OTHER
-
Session 2 (day 3)
12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods. After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®.
- OTHER
-
Session 3 (day 15)
12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to drink or eat caffeinated food/drinks 24 hours prior to night-time urine collection (at least one cup of coffee or a can of Coca-Cola®). After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®.
- OTHER
-
Session 4 (day 30)
12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods. After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®.
Sponsors & Collaborators
-
Youssef Daali
lead OTHER
Principal Investigators
-
Youssef Daali, Prof · University Hospital, Geneva
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-10-01
- Primary Completion
- 2020-12-30
- Completion
- 2020-12-30
Countries
- Switzerland
Study Locations
More Related Trials
-
Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness
NCT00401284 ·Status: COMPLETED ·Phase: PHASE2
-
Exogenous Melatonin in Postmenopausal Women with Insomnia
NCT05440734 ·Status: TERMINATED ·Phase: NA
-
Clinical Study to Assess a Dietary Supplement on Sleep Health and Quality
NCT05368909 ·Status: COMPLETED ·Phase: NA
-
Antiinflammatoric and Antioxidative Effect of Melatonin in Human Endotoxaemia
NCT01087359 ·Status: COMPLETED ·Phase: PHASE4
-
Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance
NCT02080715 ·Status: COMPLETED ·Phase: PHASE1
-
Characteristics of Sleep Patterns in Young Adults With and Without Insomnia
NCT00177216 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Melatonin on Insomnia Symptoms in Older Adults
NCT00230737 ·Status: COMPLETED ·Phase: PHASE2
-
Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms
NCT03826563 ·Status: COMPLETED ·Phase: NA
-
Melatonin Replacement Therapy in Pinealectomized Patients
NCT03885258 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers
NCT00722306 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension
NCT02963181 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study
NCT01114360 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Melatonin on Sleep Quality in Patients Dementia
NCT03066518 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Valerian on Insomnia in Menopausal Women
NCT05185219 ·Status: RECRUITING ·Phase: NA
-
Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers
NCT00716521 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance
NCT01243060 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia
NCT06062953 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Efficacy Study of EVT 201 to Treat Insomnia
NCT00380003 ·Status: COMPLETED ·Phase: PHASE2
-
Anxiolytic and Analgesic Effects of Melatonin
NCT02386319 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Nutritional Supplementation on Sleep Quality and Gut Microbiome Composition in Older Adults
NCT04078724 ·Status: COMPLETED ·Phase: NA
-
Melatonin Treatment for Induced Transient Insomnia
NCT00950885 ·Status: COMPLETED ·Phase: NA
-
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study
NCT01114373 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Melatonin Supplementation on Renal Physiology in a Habitual Sleep Restricted Population.
NCT02631148 ·Status: TERMINATED ·Phase: PHASE2
-
Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers
NCT02108353 ·Status: COMPLETED ·Phase: PHASE3
-
Benefit of IQP-AO-101 for Sleep
NCT03114696 ·Status: COMPLETED ·Phase: NA